University of Miami, Sylvester Comprehensive Cancer Center

Site:	University of Miami, Sylvester Comprehensive Cancer Center	Go to their website
Address:	1475 Northwest 12th Ave
City:	Miami
State:	FL
Zip:	33136
Country:	USA

24 trials at this site

Phase	Trial	Trial Status	Site Status	Drug	NCT#
2	Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)	Withdrawn	Not yet activated	Ripretinib plus Binimetinib	NCT05080621
3	Masitinib 2nd Line versus Sunitinib in Advanced GIST	Unknown	Active	Masitinib or Sunitinib	NCT01694277
3	A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment	Unknown	Active	Masitinib, (AB1010)	NCT00812240
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Suspended	Closed	Nivolumab + Ipilimumab	NCT02500797
1	Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma	Suspended	Closed	Dendritic Cell Vaccine	NCT01803152
1/2	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	Active	DCC-3116 + Ripretinib	NCT05957367
3	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	Recruiting	Active	Bezuclastinib plus Sunitinib	NCT05208047
2	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	Recruiting	Active	ctDNA plus Sunitinib or Regorafenib	NCT05366816
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
1	Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma	Ongoing, but not recruiting	Closed	ARQ 092	NCT01473095
2	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Not yet recruiting	Not yet activated	Bezuclastinib plus Sunitinib	NCT06208748
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Completed	Active	Rogaratinib	NCT04595747
1	A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BYL719	NCT01735968
1	PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors	Completed	Closed	PLX9486 + PLX3397	NCT02401815
1/2	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Active, not recruiting	Closed	THE-630	NCT05160168
3	Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	Active, not recruiting	Closed	Crenolanib (CP-868,596)	NCT02847429
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
3	A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)	Active, not recruiting	Active	QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib	NCT03673501
2	Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas	Active, not recruiting	Closed	Axitinib + Pembrolizumab	NCT02636725
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Active, not recruiting	Active	Temozolomide	NCT03556384

University of Miami, Sylvester Comprehensive Cancer Center

24 trials at this site

Page 1 of 2 | Next | Last